Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.61 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14663348 | 0.92 | EGFR (0.72) | EGFRIGF1RKCNH2ALKCDK2 | |
| SCHEMBL14663383 | 0.87 | EGFR (0.63) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL29974991 | 0.87 | EGFR (0.63) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL14663339 | 0.87 | EGFR (0.72) | EGFRIGF1RKCNH2CDK2DYRK1B | |
| SCHEMBL14663365 | 0.86 | EGFR (0.58) | EGFRKCNH2 | |
| SCHEMBL23294110 | 0.84 | EGFR (0.61) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL31367938 | 0.83 | EGFR (0.86) | EGFRIGF1RKCNH2ALKCDK2 | |
| SCHEMBL14718920 | 0.83 | EGFR (0.86) | EGFRIGF1RKCNH2ALKCDK2 | |
| SCHEMBL517589 | 0.83 | EGFR (0.69) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL28900516 | 0.81 | EGFR (0.75) | EGFRIGF1RKCNH2ALKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| EP-4086246-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS AS EGFR MODULATORS | AstraZeneca AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-05-06 | — | — | US | disclosed |
| US-10858336-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| EP-3686194-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686193-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3333161-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2020-02-19 | — | — | EP | disclosed |
| US-10017493-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2018-07-10 | — | — | US | disclosed |
| US-20180162832-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3333161-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2018-06-13 | — | — | EP | disclosed |
| EP-3009431-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| US-9732058-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2017-08-15 | — | — | US | disclosed |
| EP-3009431-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2736895-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2016-01-06 | — | — | EP | disclosed |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2015-04-30 | — | — | US | disclosed |
| US-8946235-B2 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | ASTRAZENECA AB (SE) | 2015-02-03 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-20180162832-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-10017493-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-10858336-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.